Bayer: Peptide deal with Gubra
Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
Foundation launches Harvard research hub
The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.
Meatable teams up with Royal DSM
Royal DSM is backing Meatable, the cultivated meat start-up, in order to develop growth media for cultivated meat.
US$21m for microbiome therapies
EnteroBiotix closes an oversubscribed Series A financing with US$21.5m. The biopharma company will use the proceeds to advance its microbiome drug pipeline.
Owlstone: US$59m for breath biopsy development
Owlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the company’s breath biopsy tests.
EU ends litigation with AstraZeneca
The EU Commission and AstraZeneca have settled their ongoing legal dispute over the supply of COVID-19 vaccine doses. They agreed to a new delivery schedule.
VectivBio expands rare disease pipeline
Swiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.
ADC Therapeutics: US$325m for ADC royalties
ADC Therapeutics is set to receive up to US$325m for a royalty share in its antibody drug conjugates Zynlonta and Cami.
Yet another blow to Merck’s cancer hopeful
GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results.
Beckley Psytech: €68m for psychedelic meds
UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the company’s pipeline of psychedelic compounds dedicated to addressing neurological and psychiatric disorders.